

## **6.1.2 ANTIMICROBIAL STEWARDSHIP**



# ANTIMICROBIAL STEWARDSHIP

Intervention Type	3 <sup>rd</sup> Q 2022	4 <sup>th</sup> Q 2022	1 <sup>st</sup> Q 2023	2 <sup>nd</sup> Q 2023	12 Month Total
De-escalation	306	321	350	359	1,336
Dose adjustment	2,705	2,979	3,123	2,991	11,798
Bug-Drug mismatch	85	97	121	135	438
IV to PO conversion	280	336	488	444	1,548
Therapeutic duplication	70	73	138	116	397
<b>Totals</b>	<b>3,446</b>	<b>3,806</b>	<b>4,220</b>	<b>4045</b>	<b>15,517</b>

# ANTIMICROBIAL STEWARDSHIP

FORMULARY UPDATES	POWERPLANS	QUALITY IMPROVEMENT
<p><b>Standardization of Restriction Process for Antimicrobials</b></p> <ul style="list-style-type: none"> <li>Ceftaroline, Dalbavancin</li> <li>Vancomycin oral liquid</li> </ul>	<p><b>Updated Post-Splenectomy Powerplan</b></p>	<p><b>Lab Updates</b></p> <ul style="list-style-type: none"> <li>Improved specificity testing via VITEK ID cards                             <ul style="list-style-type: none"> <li>Updated per CLSI standards for MICs</li> </ul> </li> <li>Optimization of Procalcitonin Laboratory based reporting</li> <li>Antibiogram Update</li> </ul>
<p><b>Formulary Additions</b></p> <ul style="list-style-type: none"> <li>Bexsero Vaccine, Nitazoxanide</li> <li>Vancomycin oral capsule</li> </ul> <p><b>Formulary Removal</b></p> <ul style="list-style-type: none"> <li>Ciprofloxacin IV/PO, Pevnar-13, Lindane Shampoo</li> </ul>	<p><b>Implementation of Disease State Specific Powerplans to Align with Joint Commission Standards:</b></p> <p>UTI and SSTI</p>	<p><b>Interdisciplinary Process Improvement</b></p> <ul style="list-style-type: none"> <li>Surgical Site Infection Team-Updated Antibiotic Guidance</li> <li>Trauma-C.diff taskforce</li> </ul>
<p><b>Formulary Streamlining</b></p> <ul style="list-style-type: none"> <li>Pneumococcal Vaccination based on new CDC recommendations</li> <li>COVID-19 Treatment Criteria</li> </ul>	<p><b>Updated C.diff Powerplan to Reflect Formulary Update</b></p>	<p><b>COVID-19 Treatment Consent</b></p>